The data analytics firm EvaluatePharma compiled the forecasts based on pharmaceutical companies’ sales projections as of December 2023. Humira, AbbVie’s best-selling anti-inflammatory drug, is notably absent from the list, as the drug lost its market exclusivity in 2023.
Here are the 10 projected best-selling drugs in 2024 and their expected global sales:
1. Keytruda (Merck) — $27.2 billion
2. Ozempic (Novo Nordisk) — $16.1 billion
3. Dupixent (Sanofi) — $13.5 billion
4. Eliquis (Bristol Myers Squibb) — $13.3 billion
5. Biktarvy (Gilead) — $12.6 billion
6. Darzalex (Johnson & Johnson) — $12 billion
7. Opdivo (Bristol Myers Squibb/Ono Pharmaceutical) — $11.3 billion
8. Comimaty (Pfizer/BioNTech) — $10.8 billion
9. Gardasil (Merck/CSL) — $10 billion
10. Skyrizi (AbbVie) — $9.9 billion
